Ajanta Pharma Limited — Q3 FY24
Ajanta Pharma reported a strong Q3 FY24 with consolidated revenue of INR 1,105 crore, up 14% YoY, driven by broad-based growth across branded generics.
bullish
high
Financial stats pending filing verification
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
US revenues to sustain at similar levels for next two quarters
Management expects US generics revenue to remain at Q2 levels for the next two quarters, factoring in new launches and market share changes.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1